Drug name
|
Target
|
Source
|
Original Clinical
Indications |
Possible studies
|
5HT |
|
|
|
|
MDL100907
|
5HT2 receptor
antagonist |
(Merrell) Sanofi-
Aventis |
Tried in schizophrenia |
Role of 5HT2 receptors in sleep
Ppsychosis
Ppsychedelics |
Deramiclane
|
5HT1A receptor antagonist |
AZ
|
Tried in depression and anxiety |
5HT in mood and cognition
|
MSD 212
? Roche also |
5HT3 agonist
|
MSD
|
? Anxiety eating
|
Appetite
Anxiety
|
Fenfluramine
|
5HT release
|
?
|
Appetite suppression |
Measuring 5HT release capacity |
mCPP |
5HT2C agonist |
None |
5HT probe |
Eating anxiety |
WAY-100635
|
5-HT1A receptor antagonist |
Wyeth
|
5-HT probe
|
Mood disorders
|
Dopamine |
|
|
|
|
SCH 23390
|
D1 antagonist
|
Schering Plough |
|
Cognition
Schizophrenia
Addiction |
GSK598809 |
DRD3 antagonist |
GSK |
|
Addiction |
Noradrenaline |
|
|
|
|
Fluparoxan
|
a2 antagonist
|
Glaxo
|
? Depression
|
Cognition
Schizophrenia |
RX811059
|
a2 antagonist
|
Pierre Fabre
|
? Parkinson’s disease |
Cognition
Schizophrenia |
Amibegron
(SR-58,611A) |
b3 agonist |
Sanofi |
Anxiety/GAD
Depression/MDD |
|
Acetylcholine |
|
|
|
|
Nicotinic
|
a7 agonist
|
EVP 6124
|
Alzheimer's disease
|
Cognition
ADHD
Schizophrenia |
Mixed |
|
|
|
|
Various ratios
|
DAT, NET, SERT, etc. |
DOV
|
Depression
|
Affective disorders
Cognition
|